Peter DeMuth
Directeur Technique/Scientifique/R&D chez ELICIO THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Profil
Peter DeMuth is currently the Chief Scientific Officer at Elicio Therapeutics, Inc. He started this position in 2022.
He holds a doctorate degree from the Massachusetts Institute of Technology, which he received in 2013.
He also has an undergraduate degree from the University of Maryland, which he obtained in 2008.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 10/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Peter DeMuth
| Sociétés | Poste | Début |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2022 |
Anciens postes connus de Peter DeMuth
| Sociétés | Poste | Fin |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/06/2023 |
Formation de Peter DeMuth
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
